

**PRTN3 Blocking Peptide(C-term)**  
**Synthetic peptide**  
**Catalog # BP19803B****Specification**

---

**PRTN3 Blocking Peptide(C-term) - Product Information**

Primary Accession [P24158](#)  
Other Accession [NP\\_002768.3](#)

**PRTN3 Blocking Peptide(C-term) - Additional Information**

**Gene ID** 5657

**Other Names**

Myeloblastin, AGP7, C-ANCA antigen, Leukocyte proteinase 3, PR-3, PR3, Neutrophil proteinase 4, NP-4, P29, Wegener autoantigen, PRTN3, MBN

**Target/Specificity**

The synthetic peptide sequence is selected from aa 243-256 of HUMAN PRTN3

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PRTN3 Blocking Peptide(C-term) - Protein Information**

**Name** PRTN3

**Synonyms** MBN

**Function**

Serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) (PubMed: [3198760](http://www.uniprot.org/citations/3198760), PubMed: [2033050](http://www.uniprot.org/citations/2033050), PubMed: [28240246](http://www.uniprot.org/citations/28240246)). By cleaving and activating receptor F2RL1/PAR-2, enhances endothelial cell barrier function and thus vascular integrity during neutrophil transendothelial migration (PubMed: [23202369](http://www.uniprot.org/citations/23202369)). May play a role in neutrophil transendothelial migration, probably when associated with CD177 (PubMed: [22266279](http://www.uniprot.org/citations/22266279)).

**Cellular Location**

Cytoplasmic granule. Secreted. Cell membrane; Peripheral membrane protein; Extracellular side. Membrane raft; Peripheral membrane protein; Extracellular side. Note=Localizes predominantly to azurophil granules (primary secretory granules) in neutrophils (PubMed:2033050, PubMed:3198760, PubMed:7897245, PubMed:18462208) Secreted upon neutrophil stimulation by TNF-alpha, lipopolysaccharide (LPS), fMLP and CXCL8/IL8 or during neutrophil transmigration (PubMed:22266279, PubMed:28240246). Following secretion tethered to the cell membrane by CD177 (PubMed:18462208, PubMed:22266279)

**Tissue Location**

Expressed in polymorphonuclear leukocytes (at protein level) (PubMed:2033050, PubMed:7897245, PubMed:3198760) Expressed in neutrophils (at protein level) (PubMed:28240246, PubMed:18462208, PubMed:21193407, PubMed:22266279, PubMed:17244676) Expressed in differentiating neutrophils (PubMed:18462208)

**PRTN3 Blocking Peptide(C-term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**PRTN3 Blocking Peptide(C-term) - Images****PRTN3 Blocking Peptide(C-term) - Background**

Polymorphonuclear leukocyte serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) and causes emphysema when administered by tracheal insufflation to hamsters.

**PRTN3 Blocking Peptide(C-term) - References**

Kallquist, L., et al. Exp. Cell Res. 316(19):3182-3196(2010)  
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)  
Kuhl, A., et al. J. Immunol. 185(1):387-399(2010)  
Abdgawad, M., et al. Clin. Exp. Immunol. 161(1):89-97(2010)  
Hajjar, E., et al. FEBS J. 277(10):2238-2254(2010)